ORIGINAL ARTICLE
Serum HIF-1α and VEGF Levels Pre- and Post-TACE in Patients with Primary Liver Cancer

https://doi.org/10.1016/S1001-9294(11)60041-2Get rights and content

Objective

To investigate the expression levels of serum hypoxia inducible factor 1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF) pre- and post-transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PLC), and correlations between prognosis factors and serum HIF-1α as well as VEGF levels.

Methods

Forty consecutive patients fulfilling diagnostic criteria for PLC undergoing TACE from March 2008 to May 2009 were enrolled into the study. The serum HIF-1α and VEGF levels of PLC patients pre- and 1 day, 1 week, 1 month post-TACE were analyzed using ELISA, and compared with that of 20 healthy volunteers. Patients were divided into complete response (CR) and partial response (PR), stable disease (SD), progressive disease (PD) groups according to the therapeutic efficacy. Pearson correlation was used to analyze the correlation between different clinical variables and serum HIF-1α and VEGF levels before TACE, and correlation between serum HIF-1α and VEGF levels was also evaluated.

Results

The expression levels of serum HIF-1α and VEGF in PLC patients were 154.94±83.29 and 264.00±148.10 pg/mL pre-TACE, and both of them were significantly higher than those in control group (23.84±8.15 and 69.78±21.42 pg/mL, all P<0.01). One day after TACE, both serum HIF-1α (570.64± 230.87 pg/mL) and VEGF levels (362.07±102.25 pg/mL) reached the peak values (all P<0.01). One week post-TACE, expression levels of them were decreased (198.62±92.11 and 283.52±145.46 pg/mL respectively), but still significantly higher than those before TACE (all P<0.01). The levels of both HIF-1α (133.96±57.02 vs. 255.74±123.44 pg/mL) and VEGF (150.96±84.89 vs. 368.95±161.90 pg/mL) in CR group 1 month post-TACE were significantly lower than those in PR+SD+PD group (all P<0.01). The level of serum HIF-1α was positively correlated with serum VEGF level (r=0.42, P<0.001). Both serum HIF-1α and VEGF levels were observed to be correlated with portal vein tumor thrombi (P<0.05) and metastasis (P<0.05).

Conclusion

The HIF-1α and VEGF might play an important role in relapse of PLC. They might be considered as predictors of the efficacy of TACE and metastasis of PLC.

References (16)

There are more references available in the full text version of this article.

Cited by (53)

  • Early assessment of chemotherapeutic response in hepatocellular carcinoma based on serum surface-enhanced Raman spectroscopy

    2022, Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy
    Citation Excerpt :

    Besides, the SERS intensity at 1654 cm−1 of post-therapeutic serum is also larger than that of pre-therapeutic serum in OR group, indicating a raised level of free amino acid (amide I) in serum three days after TACE therapy. The mechanism of TACE therapy is to deliver chemotherapeutic and embolization agents into tumor-feeding artery for selective tumor hypoxia and eventually tumor necrosis [9], further leading to the temporary increment of serum vascular endothelial growth factor (VEGF) [56]. Simultaneously, in hypoxia micro-environment, VEGF can also induce rapid pro-urokinase activation on the surface of endothelial cells, further leading to the extracellular protein hydrolysis and the release of free amino acids in serum [57], which is consistent with the findings in our study.

  • The therapeutic landscape of hepatocellular carcinoma

    2021, Med
    Citation Excerpt :

    This dose might depend on different factors, such as the tumor size, the level of hypoxia before the onset of treatment, and other factors.192 During anti-angiogenic treatments and especially after hypoxia-promoting interventions such as transarterial chemoembolization, monitoring hypoxia by quantification of HIF-1α levels in the blood could be helpful to adjust the drug dose.194–196 Anti-VEGF/VEGFR treatments lead to the development of resistance through several mechanisms, such as upregulation of VEGF or other pro-angiogenic factors, which could be targeted in combination therapies with VEGF, including ephrins, placental growth factor, FGFR, p38, and angiopoietin.193,197–200

View all citing articles on Scopus
View full text